SCHEMBL5045443

SCHEMBL5045443

COc1cccc(Cc2nc3c(N)ncnc3[nH]2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.53
HSP90AB1 P08238 1/20 0.53
DHFR P00374 1/20 0.51
ADORA1 P30542 4/20 0.47
ADORA2A P29274 3/20 0.47
ADORA2B P29275 3/20 0.47
ADORA3 P0DMS8 2/20 0.47
SLC28A2 O43868 1/20 0.46
MAP4K4 O95819 2/20 0.46
PI4KA P42356 1/20 0.44
PI4K2B Q8TCG2 1/20 0.44
PI4K2A Q9BTU6 1/20 0.44
PI4KB Q9UBF8 1/20 0.44
TP53 P04637 1/20 0.44
EGFR P00533 1/20 0.44
FGFR1 P11362 1/20 0.43
FGFR4 P22455 1/20 0.43
LTA4H P09960 1/20 0.43
MPO P05164 1/20 0.42
ROCK1 Q13464 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL870860 0.80 PI4KA (0.52) ADORA1ADORA2AMAP4K4PI4KAPI4K2B
SCHEMBL7077175 0.77 DHFR (0.59) DHFREGFRROCK1
SCHEMBL4342949 0.74 HSP90AA1 (0.53) HSP90AA1HSP90AB1DHFRMAP4K4PI4KA
SCHEMBL28119906 0.73 MAP4K4 (0.66) HSP90AA1HSP90AB1DHFRMAP4K4EGFR
SCHEMBL16486536 0.72 MAP4K4 (0.41) HSP90AA1HSP90AB1SLC28A2MAP4K4PI4KA
SCHEMBL13607781 0.72 SMN1; SMN2 (0.48) DHFRADORA1ADORA2ATP53FGFR1
SCHEMBL8807641 0.72 SMN1; SMN2 (0.52) DHFRTP53EGFRLTA4H
SCHEMBL16487299 0.71 TAAR1 (0.44) MAP4K4PI4KAPI4K2BPI4K2API4KB
SCHEMBL3965133 0.71 MAP4K4 (0.42) MAP4K4PI4KAPI4K2BPI4K2API4KB
SCHEMBL16487159 0.71 XIAP (0.38) HSP90AA1HSP90AB1MAP4K4PI4KAPI4K2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1962863-A2 ORALLY ACTIVE PURINE-BASED INHIBITORS OF HEAT SHOCK PROTEIN 90 Conforma Therapeutics Corporation (US) 2008-09-03 EP disclosed
WO-2007075572-A2 ORALLY ACTIVE PURINE-BASED INHIBITORS OF HEAT SHOCK PROTEIN 90 CONFORMA THERAPEUTICS CORPORATION (US) 2007-07-05 WO disclosed
WO-2007075572-A2 ORALLY ACTIVE PURINE-BASED INHIBITORS OF HEAT SHOCK PROTEIN 90 CONFORMA THERAPEUTICS CORPORATION (US) 2007-07-05 WO disclosed
US-20070129334-A1 Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 CONFORMA THERAPEUTICS CORPORATION (US) 2007-06-07 US disclosed
US-20070129334-A1 Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 CONFORMA THERAPEUTICS CORPORATION (US) 2007-06-07 US disclosed
US-20070129334-A1 Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 CONFORMA THERAPEUTICS CORPORATION (US) 2007-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129334-A1 Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 HSP90AB1, HSP90AA1, HSP90AB2P HSP90AA1 2/4885HSP90AB1 1/4885DHFR 561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.